Exciting news from Nanjing’s biopharmaceutical industry! “KylinRay – TPSe Advanced/Accurate Radiotherapy Treatment Planning System” developed by Frontier Development of Science (FDS) is now officially launched. GENESEEQ’s “CanScan™,” a MECD multiiCancer early detection product, has received a breakthrough FDA designation.

Nanjing proudly introduced China’s first “Miniature Two-Photon Microscope” by TRANSCEND VIVOSCOPE, now approved for market. With 1,032 high-tech biopharmaceutical enterprises, Nanjing’s R&D is thriving, supported by its resources. Nanjing boasts four specialized biopharmaceutical colleges and over 20 universities with related disciplines.

With 200 innovative platforms covering crucial stages of new drug development, Nanjing is at the forefront of biopharmaceutical innovation.